Aiosyn gets seed-investment

AI-powered Aiosyn gets pre-seed investment for clinical diagnostics

LUMO Labs’ pre-seed investment vehicle, the LUMO Fund II TTT AI, has announced an investment in Aiosyn BV. LUMO Labs is the lead investor in a syndicate with Oost NL (The East Netherlands Development Agency). The value of the deal was not disclosed.

“Investing in Aiosyn is an opportunity to improve how doctors around the world diagnose diseases,” says LUMO Labs founding partner Sven Bakkes.

Supporting pathologists with AI-powered algorithms

The diagnostics industry has seen rapid adoption of artificial intelligence and has used it in clever ways to aid early diagnosis. Aiosyn offers a clinical diagnostics platform that uses AI-powered pathology algorithms to support pathologists. With Aiosyn’s AI-powered diagnostics platform, pathologists can reach more accurate and efficient clinical decision-making.

The AI-powered pathology algorithm and the clinical diagnostics platform was developed at Radboud University Medical Centre in Nijmegen. It utilises neural networks or deep learning, a powerful form of machine learning with the ability to “identify abnormal tissue patterns such as cancer with unprecedented accuracy.”

The Netherlands-based Aiosyn team plans to use the capital to expand pathologists’ access to AI. The healthtech startup also plans to integrate its algorithms with standard pathology workflows. The algorithms will also be used to accelerate the development of biomarker-based therapeutic and patient stratification strategies for biopharma and diagnostics companies.

“The Aiosyn platform increases the understanding of diseases and, by extension, the quality of healthcare. Its highly scalable interface will allow doctors around the world, including those in developing countries, to gain access to in-depth expertise and diagnostic support,” says LUMO Labs founding partner Andy Lürling. 

Aiosyn: What you need to know

Aiosyn originates from the group of Jeroen van der Laak, head of the Computational Pathology Group from Radboud University Medical Centre (Radboudumc). Jeroen van der Laak leads the scientific work of the company while Patrick de Boer is the CEO of the startup. David Tellez and Wouter Bulten complete the leadership team as CTO and CIO, respectively.

Based in Nijmegen, Aiosyn is combining science, engineering and business expertise to transform its research into a leading AI-powered medical product for pathology. The current product portfolio of Aiosyn focuses on breast and prostate cancer diagnostics. It will soon introduce applications involving colorectal, lung and kidney diseases.

Dennis Lammers, CFO of Radboudumc Holding, says, “I am excited about the great potential of AI-powered diagnostics. Sustainable, inclusive healthcare requires accessible diagnostic tools that are highly reliable, effective and efficient.”

“At Radboudumc Holding, we see great potential in Aisoyn’s technology and team for the future of healthcare. We are delighted that LUMO Labs and Oost NL invest in this exceptional team and technology,” Lammers adds.

Aiosyn co-founder and CEO Patrick de Boer sees LUMO Labs as a “natural choice” for funding since the Dutch multi-stage capital fund focuses on AI, health and well-being. As part of this investment, Aiosyn will enter LUMO Labs’ two-year venture building programme.

“In our conversations with Sven and Andy, it became clear we were also very much aligned on the entrepreneurial and business aspects of such a partnership. Having LUMO Labs on board as our lead investor for this round, together with Oost NL, opens up a whole new range of opportunities,” says de Boer.

Sven Bakkes, founding partner at LUMO Labs, says, “At the intersection of health and innovation today there are a few exceptional founders. Patrick de Boer is one of them. The Aiosyn team not only combines science, engineering and business expertise, it has shown to excel in all three.”

1000 498 Editorial Staff
My name is HAL 9000, how can I assist you?
This website uses cookies to ensure the best possible experience. By clicking accept, you agree to our use of cookies and similar technologies.
Privacy Policy